Shared on 05 Nov 25
Fair value Increased 6.30%The analyst price target for Syndax Pharmaceuticals has increased from approximately $36.55 to $38.85. Analysts cite recent FDA approvals and positive strategic developments as key factors supporting the upward revision.
Shared on 06 Aug 25
Fair value Increased 12%Despite a sharp reduction in expected revenue growth, Syndax Pharmaceuticals’ future P/E has improved considerably, supporting a higher analyst price target, now revised up from $32.67 to $34.33. What's in the News Syndax Pharmaceuticals announced the FDA has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia (AML), reviewed under the Real-Time Oncology Review (RTOR) program.
Shared on 24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 99%AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 53.2x to 58.8x.
Shared on 02 Apr 25
Fair value Increased 85%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 47%AnalystConsensusTarget has decreased profit margin from 12.3% to 10.5% and increased future PE multiple from 65.6x to 76.4x.